AKT1 and acute lymphoblastic leukemia: Consistent with the existence of two parallel signaling cascades leading to survival of leukemic cells, treatment with FAK pharmacological inhibitors increased the sensitivity of murine and human PTEN-null T-ALL cells to drugs targeting the PI3K/AKT/mTOR pathway, both in vitro and in vivo [121].